Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with a 5% revenue increase, improved gross margin, and a significant rise in EPS by 20%. The company also reported a 25% increase in free cash flow, demonstrating strong operational efficiency. These positive financial metrics suggest a positive market sentiment, likely leading to a stock price increase in the range of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Zimmer Biomet reported revenue of $2.1 billion for Q1 2026, representing a 5% increase year-over-year. This growth was driven by strong demand for the company's orthopedic products and favorable currency exchange rates.
Gross Margin The gross margin for the quarter was 75%, up from 73% in Q1 2025. The improvement was attributed to operational efficiencies and cost-saving initiatives.
Operating Income Operating income came in at $450 million, a 10% increase compared to the same period last year. This was due to higher revenue and improved gross margins.
Net Income Net income for the quarter was $300 million, up 15% year-over-year. The increase was driven by higher operating income and lower interest expenses.
Earnings Per Share (EPS) Earnings per share were reported at $1.50, a 20% increase from Q1 2025. This was attributed to the rise in net income and share repurchase activities.
Free Cash Flow Free cash flow for the quarter was $200 million, a 25% increase year-over-year. The improvement was due to better working capital management and higher profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements disclaimer: The company acknowledges that actual results may differ materially from forward-looking statements due to a variety of risks and uncertainties.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Baird Co
Blackman TD
Blair LLC
Caitlin Cronin
Canaccord Genuity
Chain Frederick
Co Incorporated
Co Research
Cowen Research
Cronin Canaccord
Division Caitlin
Division EDT
Division Jeffrey
Division Larry
Division Lichtman
Division Marcus
Division Mathew
Division Miksic
Division Newitter
Division OBrien
Division Taylor
Division Travis
Division Vijay
EDT lady
Frederick Wise
Inc Research
Inc Senior
Incorporated Research
Ivan Tornos
Jefferies LLC
Jeffrey Johnson
LLC Research
Research Division
Zimmer Biomet
ZBH Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript
Positive4-28
The earnings call summary indicates strong financial performance with a 5% revenue increase, improved gross margin, and a significant rise in EPS by 20%. The company also reported a 25% increase in free cash flow, demonstrating strong operational efficiency. These positive financial metrics suggest a positive market sentiment, likely leading to a stock price increase in the range of 2% to 8% over the next two weeks.
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call reveals strong financial performance with a 10.9% increase in net sales and significant growth across various product lines. The Q&A section highlights strategic initiatives like sales force optimization and capital allocation towards share buybacks, reflecting confidence in future growth. Despite some pricing pressures and sales force transition disruptions, the guidance remains stable with optimistic long-term prospects. These factors suggest a positive stock price movement, supported by robust product performance and strategic focus on growth areas like ASCs and robotics.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
ZBH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
